THE INDIAN PHARMACIST Official Circular Pharmacy Logo THE INDIAN PHARMACISTLearn. Explore. Practise. Excel.
MEDICINE MONOGRAPH CODE: [10.13] ID: TIP-MED-000197

Pyridoxine Hydrochloride (Vitamin B6)

Active Ingredient / Scientific Identity: Pyridoxine Hydrochloride • Class: Pyridoxal-5'-Phosphate (PLP) Coenzyme for Amino Acid & Neurotransmitter Synthesis (Schedule H / OTC | NLEM 2022)

⚖️ Compare Profile
Generic / Entity NamePyridoxine Hydrochloride (Vitamin B6) ([10.13])
Verified Indian Brands / RefGeneric Compendial Entry (No Commercial Brand Claimed)
Pharmacological ClassPyridoxal-5'-Phosphate (PLP) Coenzyme for Amino Acid & Neurotransmitter Synthesis (Schedul
Available Dosage FormsTablets: 10 mg, 20 mg, 40 mg, 50 mg, 100 mg SR; IV Injection (for Isoniazid overdose seizures)
Regulatory ClassificationNon-Schedule / OTC or Schedule K Permitted Preparation (Medical Supervision Recommend
Key Warning & Review DateRenal & Hepatic: Safe across all CKD and hepatic stages (essential in dialysis patients due to dialytic PLP clearance)
Reviewed: 2026-11-10
Safety Matrix:⚖️ Legal Status: Non-Schedule / OTC or Schedule K Permitted Preparati✔️ Standard Clinical Dispensing Precautions

1. Clinical & Scientific Overview

Pyridoxine Hydrochloride (Vitamin B6) (TIP-MED-000197, Reference Code [10.13]) is classified under Vitamins, Minerals & Nutritional Supplements (Ch 10) as a Pyridoxal-5'-Phosphate (PLP) Coenzyme for Amino Acid & Neurotransmitter Synthesis (Schedule H / OTC | NLEM 2022). Within the Indian regulatory and compendial framework, it is governed under Non-Schedule / OTC or Schedule K Permitted Preparation (Medical Supervision Recommended for High-Dose/Therapeutic Regimens).

Verified Indian Market Examples / Compendial Status:
Representative Indian Market Examples (Edition 2.7 Ch 10 [10.13], p. 133): Benadon (Abbott — 40 mg), Pyridox, B-Long (100 mg SR); FDCs: Doxinate / Pregnidoxin (Doxylamine 10/20 mg + Pyridoxine 10/20 mg for Nausea & Vomiting of Pregnancy) — Strengths & Dosage Forms: Tablets: 10 mg, 20 mg, 40 mg, 50 mg, 100 mg SR; IV Injection (for Isoniazid overdose seizures)
Representative Indian Market Examples (Edition 2.7 Ch 10 [10.13], p. 133): Benadon (Abbott — 40 mg), Pyridox, B-Long (100 mg SR); FDCs: Doxinate / Pregnidoxin (Doxylamine 10/20 mg + Pyridoxine 10/20 mg for Nausea & Vomiting of Pregnancy) — Strengths & Dosage Forms: Tablets: 10 mg, 20 mg, 40 mg, 50 mg, 100 mg SR; IV Injection (for Isoniazid overdose seizures)
Dosage Forms & Available Strengths:
Tablets: 10 mg, 20 mg, 40 mg, 50 mg, 100 mg SR; IV Injection (for Isoniazid overdose seizures)
Routes: Oral / Parenteral / Topical as specified by formulation

3. Mechanism of Action & Pharmacodynamics

Pyridoxal-5'-Phosphate (PLP) Coenzyme for Amino Acid & Neurotransmitter Synthesis (Schedule H / OTC | NLEM 2022) acting on target receptor/enzyme pathways in Vitamins, Minerals & Nutritional Supplements (Ch 10): clinical efficacy is mediated via Pyridoxal-5'-Phosphate (PLP) Coenzyme for Amino Acid & Neurotransmitter Synthesis (Schedule H / OTC | NLEM 2022) for Mandatory prophylaxis and treatment of Isoniazid (INH)-induced peripheral neuropathy in all Tuberculosis patients (NTEP protocol); first-line treatment of Nausea and Vomiting of Pregnancy (NVP, alone or with Doxylamine); Pyridoxine-dependent neonatal seizures; sideroblastic anaemia.

4. Therapeutic Indications & Evidence-Supported Uses

  • Mandatory prophylaxis and treatment of Isoniazid (INH)-induced peripheral neuropathy in all Tuberculosis patients (NTEP protocol)
  • first-line treatment of Nausea and Vomiting of Pregnancy (NVP, alone or with Doxylamine)
  • Pyridoxine-dependent neonatal seizures
  • sideroblastic anaemia

🇮🇳 Jurisdiction & Indication Note: Indications and schedules reflect Indian compendial and regulatory records (CDSCO / Indian Pharmacopoeia & NFI / NLEM 2022). Where international reference labels (US FDA DailyMed / NCBI StatPearls) are cited for pharmacokinetic or mechanistic parameters, international approvals do not automatically imply CDSCO approval in India.

5. Educational Dosage Context, Formulations & Administration

Educational Dosing & Regimen Summary: Isoniazid Neuropathy Prophylaxis (Routine TB): 10–20 mg (half of a 40 mg Benadon tab) PO OD (Use 40–50 mg OD in high-risk TB patients: diabetes, HIV, pregnancy, alcoholism, malnutrition, CKD, or Linezolid co-therapy). Established INH Neuropathy: 50–100 mg PO OD–BD. Morning Sickness (NVP): 10–25 mg PO TDS (or Doxylamine + Pyridoxine 10/10 mg 2 tabs at bedtime)

Administration & Meal Timing: Take with or after meals (for TB patients, may be taken alongside morning 4-FDC/3-FDC tablets) | Morning (Once Daily with TB medicines); Bedtime (for Doxinate in pregnancy nausea)

6. Pharmacokinetics, Metabolism & Renal/Hepatic Adjustment

Absorption & Disposition:
Absorption, distribution, metabolism, and excretion follow class pharmacokinetic profile; verify patient renal/hepatic function.
Metabolism & Biotransformation:
Renal & Hepatic: Safe across all CKD and hepatic stages (essential in dialysis patients due to dialytic PLP clearance)
Elimination & Renal Adjustment:
Renal & Hepatic: Safe across all CKD and hepatic stages (essential in dialysis patients due to dialytic PLP clearance)
Hepatic Impairment Considerations:
Renal & Hepatic: Safe across all CKD and hepatic stages (essential in dialysis patients due to dialytic PLP clearance)

7. Contraindications, Precautions & High-Risk Warnings

Contraindications & Red-Flag Precautions:
  • PARADOXICAL HIGH-DOSE SENSORY NEUROPATHY WARNING: While 10–50 mg/day prevents neuropathy, chronic megadoses of Pyridoxine (>200–500 mg/day for months) are neurotoxic to dorsal root ganglia and CAUSE severe sensory ataxia and peripheral neuropathy! Never exceed prescribed doses

Key Clinical Precautions: Renal & Hepatic: Safe across all CKD and hepatic stages (essential in dialysis patients due to dialytic PLP clearance)

8. Adverse Effects Profile

Common & Mechanism-Related Adverse Effects:
  • None at 10–100 mg/day
  • Sensory ganglionopathy / severe peripheral neuropathy and ataxia if megadoses (>200–500 mg/d) are taken long-term
Serious / Dose-Limiting Adverse Effects:
  • Monitor for severe hypersensitivity, organ toxicity, or dose-limiting adverse events.

9. Major Drug–Drug, Drug–Food & Drug–Herb Interactions

  • CRITICAL LEVODOPA INTERACTION: Pyridoxine (>=5–10 mg/day) activates peripheral aromatic L-amino acid decarboxylase and blocks plain Levodopa — HOWEVER, this interaction does NOT occur when Levodopa is co-formulated with Carbidopa or Benserazide (Syndopa / Madopar)! High-dose Pyridoxine (>80–200 mg/d) can lower serum Phenytoin and Phenobarbital levels

10. Clinical Monitoring, Patient Counselling & Storage

Clinical & Laboratory Monitoring: Monitor clinical response, baseline renal/hepatic parameters, and relevant serum biomarkers.

Pharmacist Patient Counselling Points:

  • Patient Counselling Checklist: Every patient taking Isoniazid (AKT-4 / Akurit-4) or Linezolid for Tuberculosis must take Benadon (Vitamin B6) daily to prevent painful foot numbness and tingling; Doxinate (Vitamin B6 + Doxylamine) is the safest first-line tablet for morning sickness in early pregnancy
  • Meal & Clock Timing Instruction: Take with or after meals (for TB patients, may be taken alongside morning 4-FDC/3-FDC tablets) (Morning (Once Daily with TB medicines); Bedtime (for Doxinate in pregnancy nausea))
  • Missed Dose Protocol: Take same day if remembered
  • Geriatric Dispensing Pearl: Safe at 10–50 mg/day in older adults

Storage, Stability & Dispensing Safeguards: Store below 25°C–30°C in original moisture- and light-resistant packaging out of reach of children. Available forms: Tablets: 10 mg, 20 mg, 40 mg, 50 mg, 100 mg SR; IV Injection (for Isoniazid overdose seizures)

11. Visual Pharmacology & Mechanism Diagram (svg-v339-01-adme-12-step-journey)

THE 12-STEP ORAL DRUG JOURNEY THROUGH THE HUMAN BODY (LADME) Note: IV bolus enters Step 6 directly (F = 100%); Sublingual & Transdermal routes bypass Step 4–5 Portal First-Pass Metabolism 1. Oral Administration • Tablet / Capsule swallowed • Gastric emptying to duodenum pH 1.5–3.5 (Stomach) 2. Disintegration & Dissolution • Tablet breaks into granules • API dissolves in GI fluid Noyes-Whitney Dissolution Rate 3. GI Epithelial Absorption • Crosses intestinal villi • Passive / Active / P-gp efflux Small Intestine (Large Surface Area) 4. Portal Circulation • Mesenteric veins → Portal vein • Delivers blood to liver sinusoids Pre-systemic Venous Conduit 5. First-Pass Metabolism • Gut & hepatic CYP450 extraction • High: GTN, Propranolol, Morphine Determines Bioavailability (F = f_a × (1-E_H)) 6. Systemic Circulation • Hepatic vein → IVC → Heart • Unbound vs Albumin-bound drug Only FREE drug is active 7–8. Tissue Distribution (Vd) • Capillary permeation to organs • Blood-Brain & Placental barriers Vd = Dose / C_0 (L or L/kg) 9. Target Site of Action • Receptors (GPCR, Ion channel) • Enzymes & Carrier Transporters Pharmacodynamic Effect (E_max, EC50) 10. Hepatic Biotransformation • Phase I (CYP450 Oxidation/Hydrolysis) • Phase II (Glucuronidation/Sulfation) Converts lipophilic drug → hydrophilic metabolite 11. Renal & Biliary Elimination • Nephron: Filtration + Secretion − Reabsorption • Biliary excretion & Enterohepatic recycling Total Clearance CL_tot = CL_renal + CL_hepatic 12. Excretion from the Body • Urine (Primary polar metabolite route) • Bile/Faeces, Expired Air, Sweat, Milk Elimination Half-Life t1/2 = (0.693 × Vd) / CL
svg-v339-01-adme-12-step-journey — 8.1 Complete 12-Step Journey of an Orally Administered Drug (ADME): Figure 8.1: The 12-step physiological journey of a typical orally administered solid dosage form through Liberation, Absorption, Distribution, Metabolism, and Excretion (LADME). Note: Parenteral (IV), sublingual, and inhalational routes bypass gastrointestinal absorption and/or hepatic first-pass metabolism.

12. Authoritative References, Regulatory Sources & Editorial Disclaimer

Primary Compendial & Guideline Reference: Indian Pharmacist Desk Reference — Professional Edition 2.7 (2026–27) • Ch 10 [10.13] (p. 133)

Official Verification Portals: Indian Pharmacopoeia Commission (IPC) & National Formulary of India (NFI) • Central Drugs Standard Control Organization (CDSCO) • Ministry of Health & Family Welfare — NLEM 2022 • NCBI Bookshelf / StatPearls Pharmacology Reference • DailyMed (US FDA Official Prescribing Reference)

Last Medically & Pharmaceutically Reviewed: 2026-11-10 • Verification Status: HANDBOOK_SOURCE_CONTENT

Educational & Clinical Disclaimer: This reference profile is published solely for pharmacy education, academic study, and professional clinical reference. It does not substitute for patient-specific clinical judgement, qualified specialist oncology/medical supervision, or official CDSCO/IP prescribing information. Never self-medicate with prescription, Schedule H/H1/X, NDPS, or oncology medicines.